Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer
Medical Technologies. Assessment and Choice
doi 10.31556/2219-0678.2018.32.2.067-080
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2018
Authors
Publisher
Fund Gelios